


Certificate of Analysis

Catalog Number	BP13735
Product Name	BRD-6929

Physical and Chemical Properties

CAS No.	849234-64-6
Chemical Formula	C ₁₉ H ₁₇ N ₃ O ₂ S
Molecular Weight	351.42
Solubility	DMSO: 4.9 mg/mL (14 mM), Need ultrasonic
Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year
Chemical Structure OR Tested Image	

Product Information

Description	BRD-6929 is a selective, brain-penetrant HDAC1 and HDAC2 inhibitor (IC ₅₀ : 1 and 8 nM). BRD-6929 (Cpd-60) shows high-affinity to HDAC1 and HDAC2 (K _i : 0.2 and 1.5 nM). BRD-6929 potentiates the efficacy of gnidimacrin (a PKC Agonist) against latent HIV-1. BRD-6929 can be used for mood-related behavioral model research.
-------------	---

Targets&IC50	HDAC1:1 nM, HDAC2:8 nM
In vitro	<p>In vitro IC50 for HDAC1-9 by BRD-6929 using recombinant human HDAC enzymes and HDAC class-specific substrates. BRD-6929 and substrate are incubated for 180 min (HDAC1-3) to control for HDAC1-3 inhibition, BRD-6929 is against HDAC1, HDAC2, HDAC3 and HDAC4-9 with IC50s of 0.001 μM, 0.008 μM, 0.458 μM and >30 μM, respectively. In vitro binding affinity (Ki) and kinetics (half-life 'T1/2' in minutes) for HDAC 1, 2 and 3 incubated with BRD-6929 (10 μM), the Ki values are 2400 mins, >4800 mins, and 1200 mins for HDAC 1, 2 and 3, respectively. BRD-6929 (1 and 10 μM) does not cause an increase or decrease in overall cell number in brain region specific primary cultures. Additionally, BRD-6929 (10 μM) causes an increase in H4K12 acetylation in brain region specific primary cultures (striatum). BRD-6929 (1-10 μM; 6 hours) causes a significant increase in H2B acetylation in primary neuronal cell cultures. BRD-6929 (1-20 μM; 24 hours) induces a dose-dependent acetylation of H4K12ac with an EC50 of 7.2 μM in cultured neurons. BRD-6929 potentiates the efficacy of gnidimacrin (a PKC Agonist) against latent HIV-1.</p>
In vivo	<p>BRD-6929 (intraperitoneal injection; 45 mg/kg; single dose) exhibits a Cmax, T1/2 and AUC values of 17.7 μM, 7.2 hours, and 25.6 μM/L*hr, respectively in plasma. It shows a Cmax, T1/2 and AUC values of 0.83 μM, 6.4 hours, and 3.9 μM/L*hr, respectively in brain. BRD-6929 (intraperitoneal injection; 45 mg/kg; 10 days) acts as a deacetylase inhibitor in mouse brain. It significantly increases acetylation in each brain region by 1.5- to 2.0-fold compared to vehicle. The western blotting reveals that BRD-6929 significantly increases acetylation of histone H2B (tetra-acetylated), H3K9 and H4K12 in cortex, ventral striatum and hippocampus after the 10th daily treatment in adult male C57BL/6J mice.</p>

Analytical Data

HPLC	Shows Min >99% purity
H-NMR	Consistent with structure
Stability and Solubility Advice	<p>Information on product stability, especially in solution, has rarely been reported and in most cases we can only provide a general guideline. We recommend that once the stock solution has been prepared, it be stored in equal quantities in sealed vials and used within 1 month. Avoid repeated freezing and thawing cycles. Storage conditions for some special products should be referred to their storage details.</p>

Purdue Bioscience Inc.

750 50th St, Brooklyn, NY 11220, USA

<https://www.purduebio.com>

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022

Purdue Bioscience Inc.